IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per planLAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ...
The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein ...
Lonza has added new solutions to its TheraPEAK® portfolio, introducing AmpliCell® Cytokines and 293-GT® Medium to support ...
Transfection remains a fundamental tool for investigating gene and protein function across diverse systems. Yet variability in constructs, cell types, and delivery methods often complicates ...
OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...
News-Medical.Net on MSN
PlasmidFactory and Fraunhofer IZI join forces to advance non-viral cell and gene therapies
PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP ...
CD19 chimeric antigen receptor (CAR) T-cell therapy showed potential in treating patients with refractory systemic lupus erythematosus (SLE), with B-cell depletion and disease activity reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback